Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327076 | 0.82 | SLC7A5 (0.48) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL15958714 | 0.82 | SLC7A5 (0.48) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL9572303 | 0.81 | SLC7A5 (0.47) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL19882987 | 0.79 | DPP4 (0.48) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL18774984 | 0.79 | SLC7A5 (0.54) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL26290433 | 0.79 | SLC7A5 (0.54) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL10296149 | 0.79 | SLC7A5 (0.54) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL8269796 | 0.78 | SLC7A5 (0.44) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL17152494 | 0.78 | SLC7A5 (0.52) | SLC7A5SCN9ALARS1ANPEPRNPEP | |
| SCHEMBL20177393 | 0.77 | SLC7A5 (0.42) | SLC7A5SCN9ALARS1ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE2, BACE1, PSEN2 | SLC7A5 4443/4885SCN9A 1940/4885LARS1 4471/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | SLC7A5 4156/4885SCN9A 2545/4885LARS1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.